Weight loss typically continues, with clinical trials showing that semaglutide 2.4 mg (Wegovy) produces average weight loss of approximately 15% by week 68, while tirzepatide (Zepbound) has demonstrated weight loss of approximately 15-21% across different doses by week 72
Durvi Patel or Dr
Retatrutide goes further by: Reducing appetite Improving insulin sensitivity Increasing calorie burn Targeting visceral and metabolically active fat Supporting lean mass preservation This multi-mechanistic action is why retatrutide is being described as a next-generation metabolic therapy, rather than just a weight-loss drug
If the site does not clearly show: exact ingredient dosages in the patch, how much actually absorbs through skin, and clinical data on the finished patch product, then the claim remains marketing, not proof
The term 'processing' is very broad and encompasses activities such as collecting, storing, using your data, or sharing it with third parties
Understanding how these medications work together helps you make informed decisions with your healthcare provider
